Dyne Therapeutics, Inc. (NASDAQ:DYN)
| Market Cap | $2.90B-28.5% |
| Revenue (ttm) | $0 |
| Net Income | -$604.92M-42.7% |
| EPS | -$3.63+0.8% |
| Shares Out | 187.39M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,231,136 |
| Open | $15.91 |
| Previous Close | $16.03 |
| Day's Range | $15.41 - $16.48 |
| 52-Week Range | $14.00 - $27.31 |
| Beta | 1.21 |
| Analysts | Buy |
| Price Target | $36.88(+137.94%) |
| Earnings Date | Mar 1, 2027 |
About DYN
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
Dyne Therapeutics, Inc. Stock Analysis — InsiderScore
Dyne Therapeutics, Inc. scored higher than 1% of companies evaluated by InsiderBuying, and ranked 97th out of 103 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Dyne Therapeutics, Inc. bought $40.0K of stock across 1 purchase in the last 90 days, the largest of them $40.0K.
The average purchase added about 10% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
8 firms rating DYN in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 1, 2027Earnings report
$DYN stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in DYN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by DYN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
DYN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
DYN Revenue by Segment
| Personnel related | $32.27M | 42.50% |
| Stock-based compensation | $16.21M | 21.35% |
| Facility-related and other | $14.84M | 19.54% |
| Professional and consulting fees | $12.61M | 16.61% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New DYN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to DYN from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in DYN
| XBIState Street SPDR S&P Biotech ETF | $71.47M |
| VTIVanguard Morningstar Total Stock Market ETF | $69.56M |
| IWMiShares Russell 2000 ETF | $64.58M |
| VXFVanguard Extended Market ETF | $35.48M |
| VBVanguard Morningstar Small-Cap ETF | $31.51M |
| VBRVanguard Morningstar Small-Cap Value ETF | $20.44M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from DYN’s recent data — informational, not investment advice
What’s Behind the Score
News check: Coverage includes routine corporate filings and conference participation with no material catalysts, upgrades, downgrades, or earnings announcements directly impacting Dyne.
Recent Insider Activity
Insider Score Trend Over Time
+25.0 since Sep 22Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| IBRN | iShares Neuroscience and Healthcare ETF | 3.27% |
| SBIO | ALPS Medical Breakthroughs ETF | 2.08% |
| TSEE | T. Rowe Price Small Cap ETF | 1.89% |
| TMED | T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF | 1.75% |
| WDNA | WisdomTree BioRevolution Fund | 1.37% |
| TDNA | T. Rowe Price Biotech ETF | 1.33% |
| WSMD | Wasatch Small/Mid Cap ETF | 0.82% |
| XBI | State Street SPDR S&P Biotech ETF | 0.75% |
| BBC | Virtus Biotech Clinical Trials ETF | 0.73% |
| SGRW | Harbor Active Small Cap Growth ETF (SGRW) | 0.54% |
| JDOC | JPMorgan Healthcare Leaders ETF | 0.53% |
| TMID | T. Rowe Price Mid Cap Equity Research ETF | 0.52% |
Weight is the stock’s share of each fund’s holdings.
